Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.810
-0.010 (-0.26%)
At close: Feb 13, 2026, 4:00 PM EST
3.830
+0.020 (0.52%)
After-hours: Feb 13, 2026, 4:10 PM EST
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $861.00K in the quarter ending September 30, 2025, a decrease of -12.77%. This brings the company's revenue in the last twelve months to $2.82M, up 6.46% year-over-year. In the year 2024, Orchestra BioMed Holdings had annual revenue of $2.64M, down -4.42%.
Revenue (ttm)
$2.82M
Revenue Growth
+6.46%
P/S Ratio
56.77
Revenue / Employee
$40,257
Employees
70
Market Cap
216.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.64M | -122.00K | -4.42% |
| Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
| Dec 31, 2022 | 3.53M | 4.32M | - |
| Dec 31, 2021 | -782.00K | -6.49M | - |
| Dec 31, 2020 | 5.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 277.73M |
| Heron Therapeutics | 155.10M |
| Protalix BioTherapeutics | 61.84M |
| OmniAb | 21.09M |
| MediWound | 20.93M |
| Opus Genetics | 14.63M |
| Camp4 Therapeutics | 3.80M |
| Inhibikase Therapeutics | 1.00 |
OBIO News
- 20 hours ago - Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewsWire
- 3 months ago - Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 3 months ago - Orchestra BioMed to Host Business Update Call on November 12, 2025 - GlobeNewsWire
- 3 months ago - Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements - GlobeNewsWire